AI-generated analysis, not investment advice. The articles are written by AI, edited, and checked against company filings — but the judgements are opinions and the figures go stale. How this is made · Terms

⚠ Cash Was Spent Before It ArrivedModerate threat

Gilead Sciences (GILD) — threat to the moat

Gilead's cash fell from $10.6 billion to $3.2 billion in six months as acquisitions took more than a year of free cash flow.

Free cash flow is only as valuable as what it buys, and in 2026 Gilead spent it ahead of time. In the first half it paid $11.3 billion for acquisitions, repaid $2.8 billion of debt, paid $2.1 billion of dividends and bought back $774 million of stock, offset by $4.1 billion of net new debt1. Cash and marketable debt securities fell from $10,605 million to $3,179 million2.

Gilead uses of cash, H1 2026 ($bn)11.3Acquisitions2.8Debt repaid2.1Dividends0.8Buybacks+4.1New debt (source)Gilead Q2 2026 results release
Acquisitions alone exceeded a year of free cash flow.

That is more than a full year of free cash flow committed in six months. It leaves little room for the next opportunity or setback.

The pattern is not new for Gilead: the 2020 Immunomedics deal cost $20.6 billion in cash3, about two years of free cash flow at the time.

The new debt is cheap by recent standards but not by Gilead's old ones. The May 2026 notes carry coupons of 4.25% to 4.90%4, and the $1.1 billion term loan runs for one year5. Short borrowing to bridge acquisitions is sensible only if the next year's free cash flow arrives as expected.

The cash line is the test. If cash and marketable securities are still below $5 billion at the end of 2027, the company will have spent two years running on its credit rather than its cash.

References
  1. ReportedIn the first half it paid $11.3 billion for acquisitions, repaid $2.8 billion of debt, paid $2.1 billion of dividends and bought back $774 million of stock, offset by $4.1 billion of net new debt.
    Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - income statement, EPS, cash flow, balance sheet and 2026 guidance. — Q2 2026 · publ. 4 August 2026 · source ↗
  2. ReportedCash and marketable debt securities fell from $10,605 million to $3,179 million.
    Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - income statement, EPS, cash flow, balance sheet and 2026 guidance. — Q2 2026 · publ. 4 August 2026 · source ↗
  3. ReportedThe pattern is not new for Gilead: the 2020 Immunomedics deal cost $20.6 billion in cash, about two years of free cash flow at the time.
    Gilead Sciences Form 10-K for 2020 - the Immunomedics ($20.6 billion) and Forty Seven (about $4.7 billion) acquisitions, acquired IPR&D and the 94.7% effective tax rate. — FY2020 · publ. February 2021 · source ↗
  4. ReportedThe May 2026 notes carry coupons of 4.25% to 4.90%, and the $1.1 billion term loan runs for one year.
    Gilead Sciences Form 10-Q for the quarter ended 30 June 2026 - acquired IPR&D for Arcellx, Tubulis and Ouro, the $1.75 billion Trodelvy impairment, debt, receivables and the December 2025 agreement with the US administration. — Q2 2026 · publ. 6 August 2026 · source ↗
  5. ReportedThe May 2026 notes carry coupons of 4.25% to 4.90%, and the $1.1 billion term loan runs for one year.
    Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - income statement, EPS, cash flow, balance sheet and 2026 guidance. — Q2 2026 · publ. 4 August 2026 · source ↗
Sources
Generated October 4, 2026